Mifamurtide vs Thymalin

Head-to-head comparison of Mifamurtide (Muramyl Tripeptide Phosphatidylethanolamine) and Thymalin (Calf Thymus Peptide Fraction (Thymalin)) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyMifamurtideThymalin
CategoryImmune SupportImmune Support
Full NameMuramyl Tripeptide PhosphatidylethanolamineCalf Thymus Peptide Fraction (Thymalin)
Molecular WeightN/AN/A
Half-Life2-4 hN/A
Amino AcidsN/AN/A
Typical Dose2 mg/m25-20 mg
RouteIntravenousIntramuscular
Purity≥98%≥98%
Studies Count150120
Research StatusClinicalClinical

Mifamurtide Benefits

  • macrophage-activation
  • innate-immune-signaling
  • immune-adjuvant-research
  • cytokine-response

Thymalin Benefits

  • t-cell support
  • leukocyte recovery
  • immunomodulation
  • infection-resilience

Mifamurtide Dosing

2 mg/m2 IV|2x weekly for 12 weeks|then weekly for 24 weeks in approved regimens

Thymalin Dosing

5-10 mg IM daily|3-10 day cycles|repeat cycles after 1-4 weeks if studied

Mifamurtide Side Effects

  • fever/chills
  • fatigue
  • nausea

Thymalin Side Effects

  • injection-site discomfort
  • transient fever
  • rash/allergy

Research Overview

Mifamurtide

Mifamurtide has substantial literature as an innate immune activator and is an approved oncology adjunct in some regions. Research centers on NOD-like receptor signaling, macrophage activation, and downstream cytokine effects.

Thymalin

Thymalin appears in Soviet/Russian clinical literature as a thymus peptide complex used to normalize immune parameters after illness, surgery, or radiation exposure. Reports commonly focus on changes in lymphocyte subsets, phagocytic activity, and infection frequency rather than a single isolated peptide mechanism.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Mifamurtide stacks with:

Vitamin DZincOmega-3

Thymalin stacks with:

Vitamin DZincProbiotics
innate-immunitymacrophage-activatorlipopeptidethymic-peptideimmunomodulatorclinical-literature